Company Overview of IBC Pharmaceuticals, L.L.C.
IBC Pharmaceuticals, L.L.C. focuses on the development of novel cancer therapeutics using proprietary pre-targeting, bi-specific antibody technologies developed at Immunotech in Marseille, France. Immunotech was later purchased by Coulter Corporation, which subsequently became part of Beckman Coulter. IBC's first product candidate is currently being evaluated in Phase I/II clinical trials in France for the therapy of tumors producing carcinoembryonic antigen, or CEA. In May 2002, Immunomedics, Inc. (Nasdaq: IMMU) acquired the remaining 43% interest in IBC Pharmaceuticals, L.L.C. from Beckman Coulter, Inc.
Morris Plains, NJ
Key Executives for IBC Pharmaceuticals, L.L.C.
IBC Pharmaceuticals, L.L.C. does not have any Key Executives recorded.
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact IBC Pharmaceuticals, L.L.C., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.